HGH 191AA (50 IU Vial) Dosage Protocol
HGH 191AA is a 29-amino-acid synthetic peptide corresponding to the active fragment of native GHRH. Approved historically as a diagnostic for GH deficiency and used in research for GH-axis stimulation.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Standard / Gradual Titration (3 mL = 16.67 IU/mL)
| Week | Daily Dose (IU) | U-100 Units (mL) |
|---|---|---|
| Week 1 | 0.6 IU | 3.6 units (0.036 mL) |
| Week 2 | 0.9 IU | 5.4 units (0.054 mL) |
| Week 3 | 1.2 IU | 7.2 units (0.072 mL) |
| Week 4 | 1.5 IU | 9 units (0.09 mL) |
| Week 5 | 1.8 IU | 10.8 units (0.108 mL) |
| Week 6 | 2.1 IU | 12.6 units (0.126 mL) |
| Week 7 | 2.4 IU | 14.4 units (0.144 mL) |
| Week 8 | 2.7 IU | 16.2 units (0.162 mL) |
Frequency: Once daily by subcutaneous injection, preferably at bedtime to follow the natural nighttime GH pulse. Rotate sites to reduce lipoatrophy. The 8-week schedule climbs by about 0.3 IU per week.
Extended 12-Week Protocol (Optional)
| Week | Daily Dose (IU) | U-100 Units (mL) |
|---|---|---|
| Week 9 | 3 IU | 18 units (0.18 mL) |
| Week 10 | 3.3 IU | 19.8 units (0.198 mL) |
| Week 11 | 3.6 IU | 21.6 units (0.216 mL) |
| Week 12 | 3.9 IU | 23.4 units (0.234 mL) |
Note: Weeks 9–12 reach 3.0–3.9 IU daily, a range explored in performance and metabolic research. Higher amounts raise the likelihood of side effects such as water retention, joint discomfort, and numbness or tingling. A 16-week extension reaching about 5.1 IU daily appears in advanced protocols and calls for appropriate monitoring.
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl or roll until dissolved. Do not shake; vigorous agitation can damage the protein.
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Doses are shown in IU only. Educational purposes only; not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration (one injection per day).
| Item | 8 weeks | 12 weeks | 16 weeks |
|---|---|---|---|
| HGH 191AA vials (50 IU each) | 2 vials (92.4 IU total) | 4 vials (189 IU total) | 7 vials (319.2 IU total) |
| Insulin syringes (U-100) | 56 syringes | 84 syringes | 112 syringes |
| Bacteriostatic water (10 mL bottles) | 6 mL → 1 bottle | 12 mL → 2 bottles | 21 mL → 3 bottles |
| Alcohol swabs | 112 swabs → 2 × 100-count boxes | 168 swabs → 2 × 100-count boxes | 224 swabs → 3 × 100-count boxes |
Protocol Overview
It was historically used as a diagnostic for GH deficiency and has the longest published clinical track record of any GHRH analog. Pre-bed dosing is the most-cited protocol, aligning with the natural overnight GH pulse. Once-daily dosing fits well into a long-term protocol structure.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 14 days, protect from light |
Important Notes
How This Works
HGH 191AA is a 29-amino-acid analog of the active N-terminal portion of native GHRH. It binds pituitary GHRH receptors, stimulating endogenous pulsatile GH release. Half-life is shorter than CJC-1295 (~10 min vs ~30 min) producing a brief discrete pulse.
Potential Benefits & Side Effects
Potential Benefits
- Stimulates endogenous GH release via natural pathway.
- Pulsatile rather than continuous — preserves natural feedback.
- Sleep-quality improvements anecdotally reported.
- Body-composition effects via sustained protocols.
Side Effect Profile
- Injection-site reactions.
- Mild flushing post-dose.
- Transient water retention.
- Headache occasionally reported.
Lifestyle Factors
- Pre-bed timing aligns with natural GH pulse during slow-wave sleep.
- Avoid late-evening high-fat meals.
- Resistance training amplifies anabolic effects.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- Rotate sites with each dose.
- 90° angle with short insulin needle.